Complement Inhibitors Market

Market Size

The global complement inhibitors market size, valued at USD 12.56 billion in 2025, is projected to reach USD 14.30 billion in 2026 and USD 28.65 billion by 2035, with a CAGR of 8% during the forecast period 2026 to 2035. This market is growing steadily, driven by the rise of next-generation complement targeting technologies and expanding therapeutic applications.

Market Report: Key Takeaways

• Innovations such as small molecules, RNA therapies, and gene editing enable precise complement modulation, enhancing safety and expanding treatment scope. These advances foster new therapeutic opportunities and address limitations of current complement inhibitors industry.
• In terms of target disease indication, the hereditary angioedema segment secures 26% of the overall revenue share. This can be attributed to the fact that complement inhibitors targeting hereditary angioedema have shown significant effectiveness by slowing the progression during clinical evaluation, leading to strong uptake and FDA approvals.
• In terms of geographical regions, North America is holding 68% of the complement inhibitors market share due to the growing research, favorable regulatory guidelines, and a strong presence of top complement inhibitors companies.
• In terms of leading players, Alexion Pharmaceuticals (a subsidiary of AstraZeneca) captures the majority of the market revenue share due to several high-selling complement inhibitors, such as Ultomiris and Soliris in its pipeline.

Market Overview

The complement inhibitors have emerged as a transformative class of therapeutics targeting the complement cascade (central to innate immunity), garnering significant traction over the past few years. Complement inhibitors are helpful in reducing tissue inflammation and dampening the adaptive immune response to foreign and tissue antigens.

Owing to the potential benefits of these therapeutic drug classes, such as reduced organ damage and improved patient outcomes, numerous stakeholders across academia, industry, and healthcare sectors are proactively engaged in the research and development of these innovative therapeutic inhibitors.

Presently, more than 30 complement inhibitors drugs have been commercialized. In addition, over 155 drug programs targeting the complement pathway are under development, with most of these therapies progressing through clinical stages of development for complement inhibitors pipeline analysis.

This sector is further fueled by a wave of investments, strategic collaborations, and facility expansions, reflecting a deepening commitment to overcoming production bottlenecks. Collectively, these developments suggest that complement inhibitors are poised for strong growth, making them critical enablers of the next generation of therapeutic medicines.

Complement Inhibitors Market Trends

• Partnerships and Collaborations: The complement inhibitors industry is witnessing several partnerships, which are expected to drive growth in this market. For instance, market players, such as Teva and Invizius, are increasing collaborations and partnerships to expand the development and commercialization for complement therapeutics for a myriad of target indications. Likewise, several market players are entering into collaborations for expanding clinical trials and research on complement inhibitors.
• Shift Towards Patient-centric Delivery and Administration: New subcutaneous, oral, and long-acting formulations improve patient convenience, enable outpatient care, and support self-administration, driving better drug adherence and enhanced quality of life for complement inhibitor therapies.
• Growing Market Accessibility & Globalization: Rising awareness, better diagnostics, and regulatory incentives are driving complement inhibitor adoption worldwide, especially in emerging markets. Strategic collaborations and clinical trial growth further accelerates global access.

Industry Experts on Complement Inhibitors

Experts believe vaccination against meningococcal infections is important before initiating complement inhibitors.

During an Interview, Neelam Goyal (MD,Stanford University) stated that, “there are several challenges due to the absence of head-to-head comparisons. Patient enrollment in a REMS (Risk Evaluation and Mitigation Strategy) program is necessary. Eculizumab, despite being studied in refractory patients, remains a noteworthy option. Ravulizumab, with an extended dosing interval and efficacy in non-refractory patients, is considered a favorable alternative. Zilucoplan, a subcutaneous daily peptide, offers a unique option with its own set of considerations.”

Key Market Insights

Complement Inhibitors Market Drivers

• Rise of Next-generation Complement Targeting Technologies: Innovations such as small molecules, RNA therapies, and gene editing enable precise complement modulation, enhancing safety and expanding treatment scope. These advances foster new therapeutic opportunities and address limitations of current treatments.
• Expanding Therapeutic Applications: Complement inhibitors now target a broader range of diseases, including autoimmune, renal, neurological, and ophthalmic disorders, backed by strong clinical validation. This expansion increases the market potential and addresses unmet patient needs.

Market Share Analysis

Target Indication Insights: Lucrative Market Share Likely to be Captured by Geographic Atrophy and PNH by 2035

• Based on the target disease indication, the global market is segmented into PNH, hereditary angioedema, IgA nephropathy, atypical hemolytic uremic, ICMM glomerulonephritis, C3 glomerulopathy, geographic atrophy, ANCA - associated vasculitis, neuromyelitis optica, myasthenia gravis, sickle cell disease and CIDP.
• According to the complement inhibitors market report, presently the hereditary angioedema segment holds over 26% of the overall market share. This can be attributed to the fact that complement inhibitors targeting hereditary angioedema have shown significant effectiveness by slowing the progression during clinical evaluation, leading to strong uptake and FDA approvals.
• It is important to highlight that IgA nephropathy segment is likely to grow at a higher CAGR. This is due to the ongoing advancements and approval of new complement inhibitor therapies and increased clinical trials activity for targeting this indication.

Market Regional Insights: North America to Hold Largest Share

North America is Leading the Market

North American companies will likely dominate the market in 2035, owing to the robust research and development activities, coupled with increasing adoption of complement inhibitors. Major industry players include Amgen, AstraZeneca, Genentech, Ionis Pharmaceuticals, Kriya Therapeutics and Regeneron Pharmaceuticals.

Japan: An Emerging Growth Spot

The market in Japan is likely to grow at a relatively high CAGR (11%), during the forecast period till 2035. This is a result of increased healthcare spending and government initiatives to improve healthcare infrastructure, along with the rising prevalence rate of various chronic diseases, in this region.

Complement Inhibitors Market: Scope of the Report

Market Segments

Based on research, we have segmented the complement inhibitors opportunity into target disease indication, therapeutic area, type of molecule, target pathway, route of administration, leading drugs, key geographical regions and leading players.

Complement Inhibitors Market, by Target Disease Indication

• PNH 
• Hereditary Angioedema
• IgA nephropathy
• Atypical Hemolytic Uremic
• ICMM glomerulonephritis 
• C3 Glomerulopathy
• Geographic Atrophy
• ANCA - Associated Vasculitis
• Neuromyelitis Optica
• Myasthenia Gravis
• Sickle Cell Disease
• CIDP

Complement Inhibitors Market, by Therapeutic Area

• Cardiovascular Disorders 
• Genetic Disorders 
• Hematological and Vascular Disorders
• Infectious Diseases
• Neurological Disorders
• Neuromuscular Disorders

Complement Inhibitors Market, by Type of Molecule

• Biologics
• Small Molecules 

Complement Inhibitors Market, by Target Pathway

• Alternate Pathway
• Classical Complement Pathway 
• Lectin Pathway
• Terminal Pathway 

Complement Inhibitors Market, by Type of Therapy

• Monotherapy 
• Combination Therapy  

Complement Inhibitors Market, by Route of Administration

• Intravenous
• Oral 
• Subcutaneous 

Complement Inhibitors Market, by Leading Drugs

• Ultomiris 
• Fabhalta
• Izervay
• Syfovre
• RG6107 (Crovalimab)
• TAKHZYRO
• Empaveli
• Tavneos (Avacopan)
• ANX007
• Voydeya (ALXN2040, Danicopan)

Complement Inhibitors Market, by Key Geographical Regions

• North America 
• Europe
• China
• Japan 
• Rest of the World